Olema Pharmaceuticals inc Ordinary Shares OLMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
-
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $12.20
- Day Range
- $12.30–12.42
- 52-Week Range
- $8.58–17.60
- Bid/Ask
- $12.12 / $12.23
- Market Cap
- $705.52 Mil
- Volume/Avg
- 21,943 / 650,605
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 89
- Website
- https://www.olema.com
Comparables
Valuation
|
Metric
|
OLMA
|
CCCC
|
ARTV
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.07 | 1.64 | — |
Price/Sales | — | 11.91 | 3.88 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OLMA
|
CCCC
|
ARTV
|
|---|---|---|---|
Quick Ratio | 9.04 | 4.89 | 4.43 |
Current Ratio | 9.13 | 5.09 | 4.59 |
Interest Coverage | — | −715.67 | — |
Quick Ratio
OLMA
CCCC
ARTV
Profitability
|
Metric
|
OLMA
|
CCCC
|
ARTV
|
|---|---|---|---|
Return on Assets (Normalized) | −35.73% | −22.53% | −16.21% |
Return on Equity (Normalized) | −39.18% | −34.97% | — |
Return on Invested Capital (Normalized) | −43.92% | −30.08% | — |
Return on Assets
OLMA
CCCC
ARTV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Lqnxmzddc | Krq | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vmhyfcyx | Wxbqb | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zhjmrzngm | Thyjp | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wllnywnd | Mmdmwqt | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Bvtppff | Cng | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Xdbfcysy | Dmpw | $28.1 Bil | |||
| Moderna Inc
MRNA
| Gqsvbglg | Qzwlx | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Pgplzkh | Ftbl | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Phcyvmgl | Llyxc | $13.4 Bil | |||
| Incyte Corp
INCY
| Gvvlqfs | Czvdw | $12.7 Bil |
United States